Services Jakafi Exporters Online

Jakafi Exporters Online

We source and provide Jakafi exports online.

Jakafi (ruxolitinib, Incyte/Novartis) is a first-in-class JAK1/JAK2 inhibitor approved by the US Food and Drug Administration for treatment of people with polycythemia vera, a chronic type of bone marrow disease, who have had an inadequate response to or are intolerant of hydroxyurea.

Polycythemia vera is characterised by too many blood cells in the bone marrow which can cause the spleen to swell, bleeding problems and blood clots in the veins near the skin surface (phlebitis). In addition, it can increase the risk of stroke or heart attack.
Jakafi is the first treatment approved by the US Food and Drug Administration (FDA) for this condition. It is expected that the drug will reduce the occurrence of an enlarged spleen (splenomegaly) and the need for phlebotomy, a procedure to remove excess blood from the body.

The most common side effects in patients with polycythemia vera were low red blood cell counts (anemia) and low blood platelet counts (thrombocytopenia). The most common non-blood related side effects were dizziness, constipation and shingles.

The drug is also indicated for treatment of people with intermediate or high-risk myelofibrosis (MF), including primary MF, post–polycythemia vera MF, and post-essential thrombocythemia MF.

Derek Clarke, with more than 30 years as experience as an exporter of both branded and generics medicines, is able to source and supply products, often unavailable through other sources, quickly and efficiently.

As part of our service we offer an authorised and fully compliant online pharmacy. Our online medical prescription services are particularly beneficial to foreign healthcare professionals who can order what they require safely at the touch of a button.

As a recommended Jakafi exporter online, please contact us for more information.

+44 (0) 208 952 2061